Abstracts Archive - Page 236 of 2607 - ACR Meeting Abstracts

Abstract Number: 0363 • ACR Convergence 2024
Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
Rafal Ali¹, Yurilu Gonzalez Moret², Roua Hussein³ and Fabian Rodriguez⁴, ¹Jefferson Einstein Philadelphia, Lansdale, PA, ²Jefferson Einstein Philadelphia, Philadelphia, PA, ³Al-Mustansiriyah University/ college of medicine, New York, NY, ⁴Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…
Abstract Number: 0372 • ACR Convergence 2024
Readability Analysis of the American College of Rheumatology Patient Education Material
Quynh Giao Nguyen, Arianna Moss and Priyanka Iyer, University of California Irvine, Orange, CA
Background/Purpose: Patient education materials are an important resource to improve health education. According to the American Medical Association (AMA), education materials should not be written above a 6th grade…
Abstract Number: 0374 • ACR Convergence 2024
How Do Patient Decision Aids Enable Purposeful Shared Decision-Making in Rheumatology? An Integrative Review
Ibiyemi Oke¹, Ruoning Ni¹ and Bharat Kumar², ¹UNVERSITY OF IOWA HOSPITALS AND CLINICS, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Shared decision-making (SDM) is a process in which patients and clinicians work together to make health care decisions. Purposeful SDM (PSDM) is a problem-based…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0365 • ACR Convergence 2024
Patients’ Behaviors and Beliefs Around Dietary Changes Among a Cohort of Patients with Rheumatic Disease
Aaron Stubbs, Deeba Minhas, Anne Arewasikporn and Andrew Schrepf, University of Michigan, Ann Arbor, MI
Background/Purpose: Dietary interventions may help manage inflammation and are considered for adjunctive treatment of rheumatic diseases. Our study aimed to explore patients' behaviors and beliefs…
Abstract Number: 0368 • ACR Convergence 2024
Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®
Marc Scherlinger¹, Jean-Francois Kleinmann¹, Antonin Folliasson², Marianne Riviere³, Raphaelle Rybak⁴, Sabine Malivoir⁵, Jean-François Viallard⁶, Estibaliz Lazaro⁷, Christophe Richez⁸, Irene Machelart⁹, Nadine Magy-Bertrand¹⁰, Audrey Gorse¹¹, Gilles Blaison¹², Julien Campagne¹³, Benjamin Dervieux¹⁴, Thomas Moulinet¹⁵, Roland Jaussaud¹⁶, Pascal Roblot¹⁷, Mathieu Puyade¹⁷, Amélie Servettaz¹⁸, Pauline Orquevaux¹⁸, Julie le Scanff¹⁹, DANIEL WENDLING²⁰, Marc Andre²¹, Ludovic Trefond²¹, Perrine SMETS²², Nicolas Baillet²³, Christophe Deligny²⁴, Xavier Mariette²⁵, ARNAUD HOT²⁶, Emmanuelle David²⁷, Laurent Perard²⁸, Estelle Jean²⁹, Sarah Permal³⁰, Denis WAHL³¹, Christian Agard³², François Chasset³³, Baptiste Hervier³⁴, Pasquer Ronan², Mickael Martin¹⁷, Ludivine Lebourg³⁵, Frederic Renou³⁶, Loic Raffray³⁶, Elisabeth Diot³⁷, Cecile Fermont³⁸, Thierry Martin³⁹, Anne-Sophie Korganow³⁹, Jacques-Eric Gottenberg⁴⁰, Jean Sibilia⁴¹ and Zahir Amoura⁴², ¹Strasbourg University Hospital - National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ²Hometrix Health, Paris, France, ³Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Metz, France, ⁴Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Paris, France, ⁵APHP Pitié Salpêtrière - National reference center for autoimmune disease, Internal Medicine, Paris, France, ⁶CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, ⁷Bordeaux University Hospital, Pessac, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹CH de Bayonne - Competence center for autoimmune diseases, Internal Medicine, Bayonne, France, ¹⁰CHU de Besancon - Competence center for autoimmune diseases, Internal Medicine, Besançon, France, ¹¹CH de Chambery - Competence center for autoimmune diseases, Internal Medicine, Chambery, France, ¹²CH de Colmar - Competence center for autoimmune diseases, Internal Medicine, Colmar, France, ¹³Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹⁴CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁵CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁶CHU de Nancy - Competence center for autoimmune diseases, Internal Medicine, Nancy, France, ¹⁷CHU de Poitiers - Competence center for autoimmune diseases, Internal Medicine, Poitiers, France, ¹⁸CHU de Reims - Competence center for autoimmune diseases, Internal Medicine, Reims, France, ¹⁹CH - Competence center for autoimmune diseases, Internal Medicine, Villefranche-sur-Saone, France, ²⁰University Hospital, Besançon, France, ²¹CHU de Clermont-Ferrand - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²²Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²³CH de Basse-Terre - Competence center for autoimmune diseases, Internal Medicine, Basse-Terre, France, ²⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique, ²⁵Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ²⁶Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ²⁷HCL - Croix Rousse, Internal Medicine, Lyon, France, ²⁸Hopital Saint-Joseph, Internal Medicine, Lyon, France, ²⁹APHM - La Timone, Internal Medicine, Marseille, France, ³⁰CH Mayotte - CH Wallis-et-Futuna, Internal Medicine, Mamoudzou, Mayotte, ³¹Lorraine University, Nancy, France, ³²CHU de Nantes - National reference center for autoimmune disease, Internal Medicine, Nantes, France, ³³Dermatology, Hôpital Tenon, Paris, France, ³⁴APHP Saint-Louis - National reference center for autoimmune disease, Internal Medicine, Paris, France, ³⁵CHU de Rouen, Internal Medicine, Rouen, France, ³⁶CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ³⁷CHU de Tours - Competence center for autoimmune diseases, Internal Medicine, Tours, France, ³⁸CH de Valence - Competence center for autoimmune diseases, Internal Medicine, Valence, France, ³⁹Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, ⁴⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁴¹Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ⁴²French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Systemic Lupus Erythematosus (SLE) features unpredictable disease activity fluctuations, making flare hard to detect and significantly impairing quality of life. This highlights the need…
Abstract Number: 0370 • ACR Convergence 2024
Adolescents’ and Providers’ Perceptions of the Transition from Pediatric to Adult Rheumatology
Julia Witowska, Brett Curtis, Melanie Donahue, Sara Platte, Rebecca Northway and Jacqueline Madison, University of Michigan, Ann Arbor, MI
Background/Purpose: The transition from pediatric to adult rheumatology is a vulnerable period for adolescents and is associated with greater disease burden. Adolescents require an organized…
Abstract Number: PP12 • ACR Convergence 2024
Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care
Sarah Shaw and JP Summers, Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: As someone from the Black, Indigenous, and People of Color (BIPOC) community living with rheumatic conditions, I have experienced firsthand many challenges that people…
Abstract Number: 0890 • ACR Convergence 2024
Pervasive Inflammation Poisons Hematopoiesis and Drives Clonal Dominance in VEXAS Syndrome
Corrado Campochiaro¹, Molteni raffaella², Martina Fiumara³, Alessandro Tomelleri⁴, Elisa Diral⁵, Davide Stefanoni⁶, Angelica Varesi⁶, Alessandra Weber⁷, Roberta Alfieri⁸, Luisa Albano⁷, Maddalena Panigada⁶, Eleonora Cantoni⁶, Daniele Canarutto⁹, Luca Basso-Ricci¹⁰, Pamela Quaranta⁷, Angelo D’Alessandro¹¹, Gregorio Bergonzi¹², Marco Matucci-Cerinic¹³, Raffaella Di Micco³, Alessandro Aiuti³, Fabio Ciceri¹², Ivan Merelli³, Lorenzo Dagna¹⁴, Serena Scala³, Simone Cenci⁶, Luigi Naldini³, Samuele Ferrari³ and Giulio Cavalli¹⁵, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy, ³San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy, ⁴Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ⁵Unit of Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Lombardia, Italy, ⁶Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Lombardia, Italy, ⁷San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁸Institute for Biomedical Technologies, National Research Council, Segrate, Italy, ⁹Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, Milan, Italy, ¹⁰San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milano, Italy, ¹¹Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Autora, CO, ¹²Unit of Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ¹³University San Raffaele Milano, Milano, Milan, Italy, ¹⁴Ospedale San Raffaele, Milano, Italy, ¹⁵Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: VEXAS syndrome is an adult-onset, X-linked, life-threatening, autoinflammatory and hematological disease caused by somatic mutation in UBA1 gene. Our study aims at uncovering pathophysiology…
Abstract Number: 2457 • ACR Convergence 2024
Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study
Sara Boukhlal¹, Laurent Chouchana², Malika Saadi³, marion Casadevall¹, Pascal cohen⁴, bertrand Dunogue⁵, Anne Murarasu¹, Alexis Régent⁶, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹AP HP, paris, France, ²Cochin, Paris, France, ³Cardiology Department - Cochin Hospital, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence…
Abstract Number: 2454 • ACR Convergence 2024
Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020
Ansaam Daoud¹, Loai Dweik², Muhammad Shamim³, Haseeb Chaudhary⁴ and Omer Pamuk⁵, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²Cleveland Clinic Akron General Internal Medicine, Akron, OH, ³University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁴Case Western Reserve University, Westlake, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Of all rheumatic diseases, systemic sclerosis (SSc) has the highest disease-specific mortality, with a higher mortality risk than the general population. North America has…
Abstract Number: 2475 • ACR Convergence 2024
The Critical Role of Annual HRCT in Identifying ILD Progression and Assessing Outcome in SSc
Anna-Maria Hoffmann-Vold¹, Simon Beyeler², Liubov Petelytska³, Håvard Fretheim¹, Trond Mogens Aaløkken⁴, Mike Becker⁵, Hilde Jenssen Bjørkekjær⁶, Cathrine Brunborgg¹, Cosimo Bruni⁷, Christian Clarenbach⁸, Phuong Phuong Diep⁹, Rucsandra Dobrota⁷, Michael T Durheim¹, Muriel Elhai¹⁰, Thomas Frauenfelder⁸, Suzana Jordan⁷, Emily Langballe¹¹, Øyvind Midtvedt¹², Carina Mihai⁷, Adela Sarbu⁸, Marco Sprecher⁸, Øyvind Molberg¹³ and Oliver Distler¹⁴, ¹Oslo University Hospital, Oslo, Norway, ²University Hospital Zurich, Zürich, Zurich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴Medicine, Oslo, Norway, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸University Hospital Zurich, Zurich, Zurich, Switzerland, ⁹Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ¹⁰University Hospital zurich, Zürich, Switzerland, ¹¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ¹²Oslo University Hospital, Oslo, Oslo, Norway, ¹³Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc). Monitoring with lung function testing every 3–6 months for…
Abstract Number: 0498 • ACR Convergence 2024
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Welch¹, Yangyuna Yang¹, Joshua Baker², Katherine Wysham³, Dana Ascherman⁴, Paul Monach⁵, Gail Kerr⁶, Andreas Reimold⁷, grant Cannon⁸, Gary Kunkel⁹, William Robinson¹⁰, Michael Duryee¹, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵VA Boston Healthcare System, Boston, MA, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷Dallas VA Medical Center, Dallas, TX, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰Stanford University, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 2476 • ACR Convergence 2024
The Impact of Systemic Sclerosis Manifestations on Survival and Humanistic Burden: A Targeted Literature Review
vanessa smith¹, Zoe Marjenberg² and Elizabeth Volkmann³, ¹Ghent University Hospital, Gent, Belgium, ²Maverex Ltd, North Shields, United Kingdom, ³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease with multiple disease manifestations, including cutaneous fibrosis, musculoskeletal inflammation, Raynaud phenomenon, calcinosis and digital ulceration. Internal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].